Forxiga approved in the EU for the treatment of chronic kidney disease in patients with and without type-2 diabetes
Approval based on unprecedented DAPA-CKD Phase III data is the most significant advancement in chronic kidney disease in more than 20 yearsAstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The approval by the European Commission is based on positive results from the DAPA-CKD Phase III trial. The decision follows the recommendation for approval